{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T16:26:52Z","timestamp":1786638412251,"version":"build-2736575974"},"reference-count":29,"publisher":"American Chemical Society (ACS)","issue":"15","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-055340"],"award-info":[{"award-number":["INV-055340"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Masking the taste of unpalatable medicines is a key approach to improving treatment compliance, especially with children, where this issue is exacerbated. The P2X2\/3 purinergic receptor is a ligand-gated ion channel activated by ATP that relays information from taste cells to the brain. Inhibition of this receptor has been demonstrated to block taste perception in humans and mice, suggesting that the application of a potent and short-lived antagonist directly on the tongue could provide a solution to improve treatment compliance. The previously reported dual P2X3 and P2X2\/3 antagonist AF-353 (1) was used as a starting point for our campaign. A novel pyrazolopyrimidine core was identified using a scaffold-hopping strategy, which delivered compound 30 after SAR optimization. This novel antagonist displayed very high activity against P2X2\/3, combined with desired physicochemical properties, resulting in a more efficacious taste-blocking effect in mice when compared to AF-353 (1).<\/jats:p>","DOI":"10.1021\/acs.jmedchem.6c01145","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:33:17Z","timestamp":1785853997000},"page":"18856-18868","source":"Crossref","is-referenced-by-count":0,"title":["Discovery of\na Novel P2X2\/3 Allosteric Antagonist\nas an Efficient Bitter Taste Blocker"],"prefix":"10.1021","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0389-0744","authenticated-orcid":true,"given":"Franc\u0327ois","family":"Saint-Dizier","sequence":"first","affiliation":[{"name":"Pharmaron UK Ltd. , , , ,","place":["Hoddesdon, Hertfordshire, U.K., EN11 9FH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Campos","sequence":"additional","affiliation":[{"name":"Pharmaron UK Ltd. , , , ,","place":["Hoddesdon, Hertfordshire, U.K., EN11 9FH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bestwick","sequence":"additional","affiliation":[{"name":"Pharmaron UK Ltd. , , , ,","place":["Hoddesdon, Hertfordshire, U.K., EN11 9FH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6740-4232","authenticated-orcid":true,"given":"Jennifer A.","family":"Borthwick","sequence":"additional","affiliation":[{"name":"Pharmaron UK Ltd. , , , ,","place":["Hoddesdon, Hertfordshire, U.K., EN11 9FH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6833-6235","authenticated-orcid":true,"given":"Amy","family":"Brown","sequence":"additional","affiliation":[{"name":"Pharmaron UK Ltd. , , , ,","place":["Hoddesdon, Hertfordshire, U.K., EN11 9FH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoguo","family":"Chen","sequence":"additional","affiliation":[{"name":"Pharmaron Beijing, Company Ltd. , ,","place":["Beijing, China, 100176"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Christensen","sequence":"additional","affiliation":[{"name":"Monell Chemical Senses Center , 3500 Market Street , , ,","place":["Philadelphia, Pennsylvania, United States, 19104"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9478-5106","authenticated-orcid":true,"given":"Sebastien","family":"Degorce","sequence":"additional","affiliation":[{"name":"Pharmaron UK Ltd. , , , ,","place":["Hoddesdon, Hertfordshire, U.K., EN11 9FH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6509-0316","authenticated-orcid":true,"given":"Kevin M.","family":"Foote","sequence":"additional","affiliation":[{"name":"Pharmaron UK Ltd. , , , ,","place":["Hoddesdon, Hertfordshire, U.K., EN11 9FH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peihua","family":"Jiang","sequence":"additional","affiliation":[{"name":"Monell Chemical Senses Center , 3500 Market Street , , ,","place":["Philadelphia, Pennsylvania, United States, 19104"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verity","family":"Kennett","sequence":"additional","affiliation":[{"name":"Pharmaron UK Ltd. , , , ,","place":["Hoddesdon, Hertfordshire, U.K., EN11 9FH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziping","family":"Liu","sequence":"additional","affiliation":[{"name":"Pharmaron Beijing, Company Ltd. , ,","place":["Beijing, China, 100176"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Maclean","sequence":"additional","affiliation":[{"name":"Pharmaron UK Ltd. , , , ,","place":["Hoddesdon, Hertfordshire, U.K., EN11 9FH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Pollard","sequence":"additional","affiliation":[{"name":"Pharmaron UK Ltd. , , , ,","place":["Hoddesdon, Hertfordshire, U.K., EN11 9FH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Rowley","sequence":"additional","affiliation":[{"name":"Xelaro Ltd , ,","place":["Chelmsford, U.K., CM2 0AW"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen","family":"Smith","sequence":"additional","affiliation":[{"name":"Pharmaron UK Ltd. , , , ,","place":["Hoddesdon, Hertfordshire, U.K., EN11 9FH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8867-3407","authenticated-orcid":true,"given":"Eric P. A.","family":"Talbot","sequence":"additional","affiliation":[{"name":"Pharmaron UK Ltd. , , , ,","place":["Hoddesdon, Hertfordshire, U.K., EN11 9FH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Taylor","sequence":"additional","affiliation":[{"name":"Pharmaron UK Ltd. , , , ,","place":["Hoddesdon, Hertfordshire, U.K., EN11 9FH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Tordoff","sequence":"additional","affiliation":[{"name":"Monell Chemical Senses Center , 3500 Market Street , , ,","place":["Philadelphia, Pennsylvania, United States, 19104"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Twidale","sequence":"additional","affiliation":[{"name":"Pharmaron UK Ltd. , , , ,","place":["Hoddesdon, Hertfordshire, U.K., EN11 9FH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Watt","sequence":"additional","affiliation":[{"name":"Pharmaron UK Ltd. , , , ,","place":["Hoddesdon, Hertfordshire, U.K., EN11 9FH"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"2026081311073447400_cit1","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3389\/fddev.2025.1553286","article-title":"Poor-tasting pediatric medicines:\nPart 1. A scoping review of their impact on patient acceptability,\nmedication adherence, and treatment outcomes","volume":"5","author":"Ranmal","year":"2025","journal-title":"Front. Drug Deliv."},{"key":"2026081311073447400_cit2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fddev.2025.1555522","article-title":"Poor-tasting\npediatric medicines:\npart 2. Exploring caregiver and healthcare provider values and preferences\nfor a novel taste-blocker product to improve acceptability","volume":"5","author":"El-Sahn","year":"2025","journal-title":"Front. Drug Deliv."},{"issue":"Pt B","key":"2026081311073447400_cit3","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.physbeh.2015.05.015","article-title":"The sweetness and bitterness of childhood: Insights\nfrom basic research on taste preferences","volume":"152","author":"Mennella","year":"2015","journal-title":"Physiol.\nBehav."},{"issue":"5","key":"2026081311073447400_cit4","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1124\/molpharm.120.000071","article-title":"Inhibition of Bitter Taste from Oral Tenofovir\nAlafenamide","volume":"99","author":"Schwiebert","year":"2021","journal-title":"Mol. Pharmacol."},{"issue":"12","key":"2026081311073447400_cit5","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.cub.2010.04.043","article-title":"Modulation of bitter taste perception\nby a small molecule hTAS2R antagonist","volume":"20","author":"Slack","year":"2010","journal-title":"Curr.\nBiol."},{"issue":"2","key":"2026081311073447400_cit6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/chemse\/bjp092","article-title":"The molecular receptive ranges of human TAS2R bitter\ntaste receptors","volume":"35","author":"Meyerhof","year":"2010","journal-title":"Chem. Senses."},{"issue":"17","key":"2026081311073447400_cit7","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1111\/bph.16411","article-title":"Topical\napplication of a P2 \u00d7 2\/P2 \u00d7 3 purine receptor inhibitor\nsuppresses the bitter taste of medicines and other taste qualities","volume":"181","author":"Flammer","year":"2024","journal-title":"Br. J. Pharmacol."},{"issue":"5753","key":"2026081311073447400_cit8","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1126\/science.1118435","article-title":"ATP signaling is\ncrucial for communication from taste buds to gustatory nerves","volume":"310","author":"Finger","year":"2005","journal-title":"Science"},{"issue":"5","key":"2026081311073447400_cit9","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1113\/jphysiol.2014.281014","article-title":"Postsynaptic\nP2 \u00d7 3-containing\nreceptors in gustatory nerve fibres mediate responses to all taste\nqualities in mice","volume":"593","author":"Vandenbeuch","year":"2015","journal-title":"J. Physiol."},{"issue":"6","key":"2026081311073447400_cit10","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bmcl.2009.02.003","article-title":"Identification and SAR of novel diaminopyrimidines.\nPart 1: The discovery of RO-4, a dual P2X(3)\/P2X(2\/3). antagonist\nfor the treatment of pain","volume":"19","author":"Carter","year":"2009","journal-title":"Bioorg. Med. Chem.\nLett."},{"issue":"1","key":"2026081311073447400_cit11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11302-021-09763-0","article-title":"That was then,\nthis is now: the development of our knowledge and understanding of\nP2 receptor subtypes","volume":"17","author":"Kennedy","year":"2021","journal-title":"Purinergic Signal."},{"issue":"9974","key":"2026081311073447400_cit12","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/S0140-6736(14)61255-1","article-title":"P2 \u00d7 3 receptor antagonist (AF-219).\nin refractory chronic cough: a randomised, double-blind, placebo-controlled\nphase 2 study","volume":"385","author":"Abdulqawi","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"2026081311073447400_cit13","doi-asserted-by":"publisher","first-page":"2004240","DOI":"10.1183\/13993003.04240-2020","article-title":"Eliapixant\n(BAY 1817080), a P2 \u00d7 3 receptor antagonist,\nin refractory chronic cough: a randomised, placebo-controlled, crossover\nphase 2a study","volume":"58","author":"Morice","year":"2021","journal-title":"Eur. Respir. J."},{"issue":"6","key":"2026081311073447400_cit14","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.bmcl.2009.01.097","article-title":"Identification and SAR\nof novel diaminopyrimidines.\nPart 2: The discovery of RO-51, a potent and selective, dual P2X(3)\/P2X(2\/3).\nantagonist for the treatment of pain","volume":"19","author":"Jahangir","year":"2009","journal-title":"Bioorg.\nMed. Chem. Lett."},{"issue":"1","key":"2026081311073447400_cit15a","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00408-022-00592-5","article-title":"A Randomized, Double-Blind, Placebo-Controlled,1 2 3 4 5 6 7 8 9\n10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31\n32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53\n54 55 56 57 58 59 Parallel-Group Phase 2b Trial of P2 \u00d7 3 Receptor\nAntagonist Sivopixant for Refractory or Unexplained Chronic Cough","volume":"201","author":"McGarvey","year":"2023","journal-title":"Lung"},{"key":"2026081311073447400_cit15b","doi-asserted-by":"publisher","first-page":"128384","DOI":"10.1016\/j.bmcl.2021.128384","article-title":"Discovery of clinical candidate Sivopixant\n(S-600918): Lead optimization of dioxotriazine derivatives as selective\nP2 \u00d7 3 receptor antagonists","volume":"52","author":"Kai","year":"2021","journal-title":"Bioorg. Med.\nChem. Lett."},{"key":"2026081311073447400_cit16","doi-asserted-by":"publisher","first-page":"128820","DOI":"10.1016\/j.bmcl.2022.128820","article-title":"Discovery\nof 5-methyl-1H-benzo[d]imidazole\nderivatives as novel P2 \u00d7 3 Receptor antagonists","volume":"72","author":"Bae","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"6","key":"2026081311073447400_cit17a","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1164\/rccm.202409-1752OC","article-title":"Camlipixant\nin Refractory Chronic Cough: A Phase 2b, Randomized, Placebo-controlled\nTrial (SOOTHE)","volume":"211","author":"Smith","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2026081311073447400_cit17b","unstructured":"(b)\n          \n            \n              Garceau, D.; Matzouranis, A.; Bellini, R.; Payza, K.; Chauret, N.; Browne, S. E.; et al.\n          Selective P2 \u00d7\n3 modulators\n          US 10111883 B1\n          2018."},{"issue":"9","key":"2026081311073447400_cit18a","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/00003088-200241090-00003","article-title":"Oral mucosal\ndrug delivery: clinical pharmacokinetics and therapeutic applications","volume":"41","author":"Zhang","year":"2002","journal-title":"Clin. Pharmacokinet"},{"issue":"3","key":"2026081311073447400_cit18b","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1517\/17425247.2011.553217","article-title":"Advances in\norodispersible films for drug delivery","volume":"8","author":"Hoffmann","year":"2011","journal-title":"Expert\nOpin. Drug Deliv."},{"issue":"178","key":"2026081311073447400_cit18c","doi-asserted-by":"publisher","first-page":"113983","DOI":"10.1016\/j.addr.2021.113983","article-title":"Orodispersible\nfilms: Conception to quality by design","volume":"178","author":"Gupta","year":"2021","journal-title":"Adv.\nDrug Delivery Rev."},{"issue":"9","key":"2026081311073447400_cit18d","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/00003088-200241090-00003","article-title":"Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic\napplications","volume":"41","author":"Zhang","year":"2002","journal-title":"Clin. Pharmacokinet."},{"issue":"19","key":"2026081311073447400_cit19","doi-asserted-by":"publisher","first-page":"4939","DOI":"10.1073\/pnas.1800907115","article-title":"Druggable\nnegative allosteric site of P2 \u00d7 3 receptors","volume":"115","author":"Wang","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2026081311073447400_cit20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/978-1-0716-1221-7_13","article-title":"FLIPR\nCalcium Mobilization Assays\nin GPCR Drug Discovery","volume":"2268","author":"Woszczek","year":"2021","journal-title":"Methods Mol. Biol."},{"issue":"6","key":"2026081311073447400_cit21","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/j.1476-5381.2010.00796.x","article-title":"AF-353,\na novel, potent and orally bioavailable\nP2 \u00d7 3\/P2 \u00d7 2\/3 receptor antagonist","volume":"160","author":"Gever","year":"2010","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"2026081311073447400_cit22","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1111\/j.1476-5381.2011.01749.x","article-title":"Biased\nsignalling and allosteric machines: new vistas and challenges for\ndrug discovery","volume":"165","author":"Kenakin","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"2026081311073447400_cit23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1476-5381.1992.tb14293.x","article-title":"Combined\ndose-ratio analysis of cholecystokinin receptor antagonists, devazepide,\nlorglumide and loxiglumide in the guinea-pig gall bladder","volume":"106","author":"Bishop","year":"1992","journal-title":"Br. J. Pharmacol."},{"issue":"11","key":"2026081311073447400_cit24","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1021\/acs.oprd.0c00248","article-title":"Development\nof a Green and Sustainable Manufacturing\nProcess for Gefapixant Citrate (MK-7264). Part 1: Introduction and\nProcess Overview","volume":"24","author":"Ren","year":"2020","journal-title":"Org. Process Res. Dev."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.6c01145","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/15\/18856\/66377291\/acs.jmedchem.6c01145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/15\/18856\/66377291\/acs.jmedchem.6c01145.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:24:46Z","timestamp":1786634686000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/69\/15\/18856\/5242076\/Discovery-of-a-Novel-P2X2-3-Allosteric-Antagonist"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":29,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8,3]]},"published-print":{"date-parts":[[2026,8,13]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.6c01145","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]}}}